MG
TARA icon

Michael Gelband’s Protara Therapeutics TARA Stock Holding History

Michael Gelband’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-116,305
Closed -$606K – 2055
2026
Q1 		$606K Buy
+116,305
New +$688K ﹤0.01% 1140
2020
Q2 		– Sell
-9,412
Closed -$216K – 2021
2020
Q1 		$216K Buy
+9,412
New +$274K 0.01% 763

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Michael Gelband's TARA Position: Q2 2026 in Review

Michael Gelband sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 116,305 shares — an estimated $606K sold.

Michael Gelband first reported a position in TARA in Q1 2020 and held it in 2 quarters. The position peaked at $606K in Q1 2026. 118 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Michael Gelband reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 116,305 Protara Therapeutics shares in Q2 2026, an estimated $606K.
  • Michael Gelband first reported a position in Protara Therapeutics in Q1 2020 and held it in 2 quarters.
  • Michael Gelband's Protara Therapeutics position peaked at $606K in Q1 2026.
  • 118 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.